Ablynx Ups Profile Stateside With $200m Nasdaq Listing

Success in the clinic with caplacizumab for aTTP and a big IPO in the USA has put the Belgium-headquartered group in the spotlight.

Dollar Airplane_1200
Flying high: Ablynx IPO in the US has been a success • Source: Shutterstock

Fresh from its clinical success with caplacizumab, Ablynx NV has priced its initial US public offering totaling $200m, propelling the company's market capitalization over the €1bn mark.

The Belgium-headquartered group has listed on the Nasdaq after selling 11.4 million American Depositary Shares (ADS) priced at $17.50 each....

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip